Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T for BCMA-positive Multiple Myeloma
NCT03093168Phase 1Unknown
- Start
- Feb 2017
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA CAR-T cells in multiple myeloma (MM). Primary endpoint: Safety measured by occurrence of study related adverse effects at 6 months. Status: unknown.
02
Drugs
anti-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03093168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093168.